News
Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?
Researchers have identified two new drug families that block a key tuberculosis (TB) enzyme, offering hope for novel ...
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday.
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results